Corina-Miruna Lungu

Mr. Corina-Miruna Lungu

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
PLPetru Fabian Lungu
Petru Fabian Lungu
CLCorina-Miruna Lungu
Corina-Miruna Lungu
Alin Stelian CiobicăAlin Stelian Ciobică
Alin Stelian Ciobică
Ioana - Miruna BalmusIoana - Miruna Balmus
Ioana - Miruna Balmus
RVRaluca Vitalaru
Raluca Vitalaru
IGIrina Gurzu
Irina Gurzu
The majority of schizophrenia-affected individuals display deficiencies in multiple cognitive domains such as attention, working memory, long-term memory, and learning, deficiencies that are stable throughout the disease. The purpose of this narrative review was to examine the effect of antipsychotics on several cognitive domains affected by schizophrenia. Methods: We searched MEDLINE, Elsevier, Scopus, and DOAJ databases for randomized controlled trials and other studies investigating the effects of typical and atypical antipsychotics on cognition in patients with schizophrenia in studies conducted in the last decade. Results: The majority of studies included in this review showed that antipsychotics (especially SGAs) have positive effects on both cognition and general psychopathology of schizophrenia. We mention that treatment with antipsychotic substances represents an ongoing effort of the researchers, who are constantly searching for the best approach to meet the mental health needs of schizophrenia patients. Conclusions: Even with those positive results, it should be noted that more studies are needed in order to fully observe the various effects of certain antipsychotic substances on cognition.

28 June 2023 in Brain Sciences
Verified
Journal Article
Open access
PDF file
PLPetru Fabian Lungu
Petru Fabian Lungu
CLCorina-Miruna Lungu
Corina-Miruna Lungu
Alin Stelian CiobicăAlin Stelian Ciobică
Alin Stelian Ciobică
Ioana - Miruna BalmusIoana - Miruna Balmus
Ioana - Miruna Balmus
ABAlexandra Bolos
Alexandra Bolos
ALAlina Costina Luca
Alina Costina Luca
Metacognition essentially represents “thinking about thinking”, or the individual’s capacity to control and monitor their own cognitive processes. Metacognition impairment in schizophrenia represents a core feature of the disease, and, in the last fifteen years, the subject has evolved into a growing study area concentrating on a wide variety of processes, such as clinical insight, autobiographical memory, cognitive beliefs, reasoning, and memory biases. Since metacognition is a complex subject, we wanted to focus on the different nuances of metacognition transposed into the lives of patients diagnosed with either schizophrenia or a schizoaffective disorder. Therefore, this narrative review aims to analyze the literature in order to provide an insight regarding the current methods and approaches in the study of metacognition in schizophrenia or schizoaffective disorders, as well as the results provided. Results from the reviewed studies showed that patients with schizophrenia have a lower metacognitive ability, which is strongly reflected in their lives. Studies to date have highlighted the interaction between schizophrenia symptoms and metacognition, which shows how metacognition impacts work performance, autobiographical memory, motivation, the severity of symptoms, and social cognition.

14 October 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
PLPetru Fabian Lungu
Petru Fabian Lungu
LHLuminita Diana Hritcu
Luminita Diana Hritcu
MNMircea Nicusor Nicoara
Mircea Nicusor Nicoara
ASAlexandra Savuca
Alexandra Savuca
ACAlexandrina Curpan
Alexandrina Curpan
Gabriel-Ionut Ionut PlavanGabriel-Ionut Ionut Plavan
Gabriel-Ionut Ionut Plavan
Background: Schizophrenia (SCZ) is a psychiatric disorder that negatively impacts patients’ quality of life, frequently inducing difficulties in managing day-to-day tasks. Current research is persistently working on finding therapeutic methods to alleviate the positive and negative symptoms, as well as the associated cognitive dysfunctions. Since the main therapeutic approach in SCZ is antipsychotics, the current study aimed to explore the effects of typical (haloperidol, HAL) vs. atypical (risperidone, RIS) antipsychotics on the cognitive functions in an animal model (Danio rerio) of SCZ, obtained by ketamine (KET) administration. Methods: The cognitive evaluation of the zebrafish was performed using memory and learning tests based on two stimuli: food and colours (i.e., T memory test and novel object recognition (NOR) test, respectively). Results: According to the behavioural analyses, HAL significantly enhanced the cognitive performances of the SCZ model, as compared to RIS. Nonetheless, HAL and RIS exhibited comparable effects on social behaviour in the SCZ model. Interestingly, both HAL and RIS enhanced the interest for the novel object in the NOR test in control individuals, but significantly decreased it in the SCZ model. The interaction between KET and RIS could exhibit sedative properties. Conclusions: Both typical (HAL) and atypical (RIS) antipsychotics alleviated cognitive, socio-affective, and decision-making impairments in a ketamine-based adult zebrafish model of schizophrenia. HAL was more effective, particularly in food-stimulated decision-making compared to novel object or social stimuli. Colour influenced behavioural responses, with silver linked to prey/feeding effects and red perceived as aversive. The KET–RIS combination induced exploratory impairments, possibly due to sedative effects. These findings highlight differential pharmacological and ethological modulation of schizophrenia-like behaviours.

19 March 2026 in BRAIN. BROAD RESEARCH IN ARTIFICIAL INTELLIGENCE AND NEUROSCIENCE
Verified
Journal Article
Open access
PDF file
PLPetru Fabian Lungu
Petru Fabian Lungu
CLCorina-Miruna Lungu
Corina-Miruna Lungu
BNBogdan Novac
Bogdan Novac
ONOtilia Novac
Otilia Novac
CACristina Albert
Cristina Albert
Alin Stelian CiobicăAlin Stelian Ciobică
Alin Stelian Ciobică
Metacognitive impairments are central to schizophrenia and strongly linked to limited insight and poor functional outcomes. While atypical antipsychotics effectively reduce positive symptoms, their influence on metacognition remains unclear. This pilot study explores how different antipsychotic regimens may affect metacognitive belief patterns, while also considering artificial intelligence (AI) only as a future direction for augmenting cognitive interventions. Twelve participants (eight with schizophrenia, four healthy controls) were assessed using the Metacognitions Questionnaire-30 (MCQ-30). Patients were prescribed either clozapine with amisulpride or two-drug combinations selected from risperidone, aripiprazole, and quetiapine. Between-group comparisons were conducted using one-way ANOVA with post hoc tests. Effect sizes and post hoc power analyses were calculated. No significant differences emerged in cognitive confidence or cognitive self-consciousness. However, patients receiving dual-drug combinations from risperidone, aripiprazole, and quetiapine reported stronger positive beliefs about worry and greater perceptions of thought dangerousness. These trends suggest that certain multi-drug regimens may intensify maladaptive metacognitive beliefs. This study provides preliminary observations that antipsychotic polypharmacy may influence metacognitive functioning in schizophrenia. While AI was not applied here, future research could examine whether digital tools may one day support metacognitive awareness and regulation alongside pharmacological care.